Home›Sensitive Cyp3a Substrates›Sensitive Cyp3a Substrates + Lenacapavir Sodium

Does Sensitive Cyp3a Substrates Interact with Lenacapavir Sodium?

CDI records a moderate classification for Sensitive Cyp3a Substrates and Lenacapavir Sodium. The stored summary is: YEZTUGO may increase concentrations of sensitive CYP3A substrates, resulting in increased risk of adverse events. Monitoring or dosing adjustments may be needed. The mechanism involves moderate cyp3a inhibition by lenacapavir. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Evidence status

A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.

Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.

Saved label reference on DailyMed. This identifier has not been checked here as support for the current claim.

Stored CDI classification: Moderate
Management: Confirm exact products with your pharmacist
Data Source: U.S. FDA via OpenFDA

Recorded Mechanism

Moderate CYP3A inhibition by lenacapavir

What To Tell Your Doctor or Pharmacist

If you are taking Sensitive Cyp3a Substrates and your doctor is considering prescribing Lenacapavir Sodium (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Ask whether any dosage adjustments are needed
Never stop or change either medication without first consulting your healthcare provider

💊 Sensitive Cyp3a Substrates(Fluorimax Sensitive)+💊 Lenacapavir Sodium(Yeztugo)

Severity & Interaction Details

🟡

moderate

Stored CDI classification: moderate

A current source comparison has not been recorded for this claim. The stored classification does not determine the clinical significance for your exact products or circumstances.

Severity scale

MinorContra

On record

Yes

Drug A class

—

Drug B class

—

Source

NLP:lenacapavir sodium

What this means in plain English

YEZTUGO may increase concentrations of sensitive CYP3A substrates, resulting in increased risk of adverse events. Monitoring or dosing adjustments may be needed.

About Sensitive Cyp3a Substrates and Lenacapavir Sodium

Lenacapavir Sodium is also sold under the brand name Yeztugo. Lenacapavir Sodium additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:lenacapavir sodium

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Sensitive Cyp3a Substrates and Lenacapavir Sodium against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.